Meda: FDA Approves Azelastine Eye Drops Unit Dose

Main Category: Eye Health / Blindness
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 10 Jul 2008 - 5:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The U.S. Food and Drug Administration (FDA) has approved Meda's (STO:MEDAA) registration application for azelastine eye drops in unit dose (Optivar Unit Dose). The substance azelastine is an antihistamine and the eye drop formulation is approved for treatment of allergic conjunctivitis in adults and pediatrics.

Meda is conducting a broad development program for the azelastine substance, both as azelastine eye drops and azelastine nasal spray. Azelastine eye drops sample is one part of that development program.

MEDA AB (publ) is an international specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented with own organisations in 26 countries and with more than 1 500 employees within marketing and sales. Meda's products are sold in approximately 120 countries world-wide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange.

MEDA AB